Journal
BIOLOGICAL PSYCHIATRY
Volume 78, Issue 10, Pages 693-701Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.biopsych.2015.01.015
Keywords
Behavior; 5-Lipoxygenase; Frontotemporal dementia; Synapse; Tau protein; Tauopathy; Transgenic tau mice
Categories
Funding
- National Institutes of Health [AG033568, P30 DA 13429, T32 DA 07237]
- Alzheimer Art Quilt Initiative
- Alzheimer's Association
- Bright Focus Foundation
Ask authors/readers for more resources
BACKGROUND: 5-Lipoxygenase (5-LO) is a protein widely distributed in the central nervous system where it modulates amyloidosis and memory impairments in transgenic mouse models of Alzheimer's disease. However, no data are available as to whether 5-LO is elevated in human tauopathy or if it directly influences tau pathology in a relevant model of the disease. METHODS: We assayed 5-LO levels in brain samples from patients with tauopathy and transgenic tau mice, and we evaluated the effect of 5-LO pharmacologic inhibition on the phenotype of these mice. RESULTS: The 5-LO protein is upregulated in human tauopathy and transgenic tau mice brains. Pharmacologic blockade of 5-LO in tau mice resulted in significant memory improvement, rescue of synaptic integrity and dysfunction, and reduction of tau pathology via a cdk5-dependent mechanism. CONCLUSIONS: These results establish a key role of 5-LO in the development of the tau pathology phenotype and demonstrate it to be a novel viable therapeutic target for the pharmacologic treatment of human tauopathy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available